AbstractBySubCategory

Prevention, Diagnosis, and Screening

Cancers of the Colon, Rectum, and Anus

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142. Michael J. Overman

519

Molecular variances between rectal and left-sided colon cancers. John Marshall

522

Expression of COX-2 and 15-PGDH in adenomas removed during pretreatment colonoscopy to predict chemopreventive efficacy of the selective COX-2 inhibitor, celecoxib. Jiping Wang

524

Cost-effectiveness of surveillance after curative resection (CR) of metastatic colorectal cancer (CRC). Richard M. Lee-Ying

526

Comparing mortality of colorectal cancer and gastrointestinal bleeding among patients with long-term use of low dose aspirin: A population-based study of 689,209 patients. Joseph Sung

527

Importance of genetic testing for patients with multiple colorectal cancer primaries. Caroline Elsas

528

Effect of thymidine kinase 1 expression on prognosis and treatment outcomes in refractory metastatic colorectal cancer: Results from two randomized studies of TAS-102 versus a placebo. Takayuki Yoshino

529

Characterization of tumor mutation burden (TMB) in gastrointestinal (GI) cancers. Mohamed E. Salem

530

Comparative effectiveness of initiating colorectal cancer (CRC) screening (Scr) at age 45. Afsaneh Barzi

531

Do patients and doctors have the same conversation about colorectal cancer screening? James Austin Talcott

532

Impact of adjuvant chemotherapy on recurrence risk in stage II colon cancer. Taiwo Adesoye

533

Underuse of microsatellite instability testing and predictors of high microsatellite instability disease among young colorectal cancer patients. Talha Shaikh

534

The association between insurance status and survival in patients with stage III colon cancer. Aabra Ahmed

535

Awareness and misconceptions of colorectal cancer risk factors among laypersons and physicians. Jerome Viguier

536

What about the guys? An assessment of gender differences in hereditary colorectal cancer testing. Carin Espenschied

537

Molecular characterization of squamous cell carcinoma of the anal canal (SCCA). Benjamin Adam Weinberg

538

Changes in platelet/lymphocyte ratio after CRT to predict oncologic outcome in patients with rectal cancer. In Hee Lee

539

Direct access screening colonoscopy as a safe and effective approach to increasing colorectal cancer screening. Joaquin J Estrada

540

Performance of 18FDG-PET in the management of non-metastatic HIV+ anal squamous cell carcinoma (ASCC). Nabil Baba Hamed

541

Incidence of colorectal carcinoma following liver transplantation: A retrospective analysis using the United Network for Organ Sharing (UNOS) database. Mridula Krishnan

542

Effect of colon cancer sidedness compared to tumor biology on stage-specific survival. Ahmed Dehal

543

The correlation between mismatch repair status and clinicopathological characteristics in Chinese colorectal cancer patients. Zhi-tao Xiao

544

Topographical incidence and survival analysis of gastrointestinal tract cancer in adolescent and young adults compared with older adults in the United States. Oren Hannun Levine

545

Preoperative evaluation of heat shock protein 47 expression to identify patients with colorectal cancer with lymph node metastasis and poor prognosis. Koichiro Mori

546

Tracking emerging KRAS, BRAF and EGFR mutations through ccfDNA in colorectal cancers treated with EGFR blockade. Takeshi Yamada

547

Demographic factors and rate of lymph node evaluation in colon cancer stage II using National Cancer Database (NCDB). Ahmed Ibrahim Tahseen

548

Vitamin D levels and its relationship with successful completion of adjuvant chemotherapy and improved survival in early stage colorectal cancer patients. Khurram Bilal Tariq

549

Association of ongoing systemic inflammatory response (SIR) at diagnosis with lymph node retrieval and node positivity in patients undergoing surgery for colonic cancer. Ross Dolan

550

Prognostic value of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with colorectal cancer. Jae Hyun Kim

551

Octogenarian patients with colorectal cancer: Characterizing an emerging clinical entity. Hadar Goldvaser

552

Cardiotoxicity in Chinese cancer patients treated with 5-fluorouracil or capecitabine: A multicenter prospective observational study. Gong Chen

553

Demographic, clinical, and outcomes characteristics associated with screening colonoscopy in colorectal cancer patients. Samantha Ann Armstrong

554

Correlation between total lesion glycolysis in 18F-FDG PET/CT and KRAS mutation and clinical features in patients with resectable colon cancer. Ji Hyung Hong

555

Associations between regorafenib-induced adverse events (AEs) and efficacy in metastatic colorectal cancer (mCRC). Takeru Wakatsuki

556

Relationship between primary tumor location and prognosis in metastatic colorectal cancer patients treated with irinotecan/5-FU/leucovorin (FOLFIRI). Qianqian Yu

557

Evaluation of systemic inflammation-based prognostic scores in patients with advanced colorectal cancer receiving palliative pelvic radiotherapy (RT). Ross Dolan

558

Meat and fish consumption and risk of colorectal adenomas in Korea. Sun Young Yang

559

The efficacy of aprepitant for the patients receiving FOLFOXIRI and FOLFIRINOX: A phase II study. Yukami Hiroki

560

Community that pays together stays together: Sharing of resources for colorectal cancer screening and treatment of the underserved population. Katie E Dowd

561

The role of early postoperative PET-CT in patients with pathological stage III colon cancer: Results from a large single institution study. Assaf Moore

562

Investigations of a novel diagnostic technology for colorectal cancer. Hongmei Tao

564

Inequality trends in proximal and distal colon cancers. Daniel David Bodek

565

Impact of CEA alone or as part of a high intensity surveillance strategy in detecting curative colorectal cancer recurrence: A systematic review and meta-analysis. Marck Mercado

566

Predictors of circulating tumor-derived methylated BCAT1 and IKZF1 DNA in colorectal cancer patients. Erin L Symonds

567

Validation of diagnosis codes to identify side of colon in an electronic health record registry. Patricia Luhn

568

Vascular emboli as a prognostic factor in patients with stage III colorectal cancer undergoing radical surgery. Haiping Pei

570

Safety and tolerability profile of raltitrexed in Chinese patients with locally advanced or recurrent and metastatic colorectal cancer: A phase IV trial. Shukui Qin

571

Clinicopathological features and prognostic factors of colorectal neuroendocrine neoplasms. Mengjie Jiang

572

Clinicopathological associations and prognostic implications of KRAS mutation in metastatic colorectal cancer (CRC) population over 9 years at a single institute. Shruthi Melinamani

573

Prevalence of pathogenic mismatch repair mutations in an Irish cohort after clinical and molecular pre-selection. Michael P. Farrell

574

Systemic inflammation score (SIS) to predict the effect of the postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. Yoshiyuki Suzuki

575

Long-standing Crohn’s disease and its implication on anal squamous cell cancer management. Sara Moncrief

576

Multivariate analysis of determinant factors in adjuvant chemotherapy (AC) utilization in patients with stage II colon cancer (CC): Analysis of the National Cancer Database (NCDB). Donny V. Huynh

577

Aspirin in the prevention of colorectal cancer recurrence. Nimisha Kumari

578

The relationship between the degree of aberrant methylation in colorectal cancer tissue and appearance of tumor-derived DNA in blood. Erin L Symonds

579

Relationship between tumor location and oncogenes mutations (RAS, BRAF, and PIK3CA) in colorectal cancer. Daisuke Inagaki

580

CT and PET-CT for detection of synchronous lesion in patients with colorectal cancer obstruction. Hyun Ho Choi

581

The impact of pulmnary emphysema evaluated by CT on lung metastasis in rectal cancer. Naoyuki Toyota

582

Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome. Stacie Hudgens

583

Clinical utility of quasimonomorphic variation range (QMVR) on the determination of microsatellite instability (MSI) status in Japanese patients (pts) with colorectal cancer (CRC): GI-SCREEN-CRC-MSI sub-study 01. Hideaki Bando

TPS808

A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602. Michio Nakamura

TPS809